Top Industry News

The latest from small and Emerging Pharma companies featuring Agomab Therpeutics, Corxel Pharmaceuticals, Insilico Medicine, Hygtia Therapeutics, Kuva Labs, Lisata Therapeutics, and Valneva  For news on the large and mid-sized bio/pharmaceutical companies, see…

AbbVie has announced it will commit $100 billion in US research and development (R&D) and capital investments, including manufacturing, over the next decade (as reported on January 12, 2026). In…

Novartis has announced plans to build a new US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida. The facility represents another milestone in the company’s $23-billion US-based investments first…

Eli Lilly and Company and Nvidia, the high-tech giant and producer of graphics processing units, systems on chips, and application programming interfaces for data science, high-performance/accelerated computing, and artificial intelligence…

President Donald Trump has issued a proposal, dubbed the Great Healthcare Plan, as a means to lower drug prices, reduce health insurance premiums and increase price transparency in the US…

The latest from CDMOs, CMOs, and suppliers featuring Fujifilm, Thermo Fisher Scientific, Kindeva, Zydus Lifesciences, Becton Dickinson, Lupin/PolyPeptide, Fresenius Kabi/TQ Therapeutics, Bionova Scientific/Syenex, Symbiosis, Kincell, Charles River Laboratories, West Pharmaceuticals,…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring AbbVie/RemeGen, Novartis/SciNeuro Pharmaceuticals, Teva, Bayer, Asahi Kasei and Jazz Pharmaceuticals. For the latest news roundup on small and…

The latest from small and Emerging Pharma companies featuring Caldera, Lyra Therapeutics, Orca Bio and Travere Therapeutics. For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. *…

Johnson & Johnson (J&J) became the latest bio/pharmaceutical company this week (January 8, 2026) to reach a deal with the US government over US drug pricing and tariffs amid increasing…

Johnson & Johnson (J&J) has completed its $3.05-billion acquisition of Halda Therapeutics, a clinical-stage bio/pharmaceutical company focused on oral therapies for multiple types of solid tumors, including prostate cancer. The acquisition was announced in November…